For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
> It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
Cancer is a problem that can be solved, and it needs to be solved asap. Cancer too often gets either relegated to "Actually, statistically it's very unlikely" by people who don't have it or stylized to the God of Death that unlike other illness we won't solve anytime soon. There is no time to be lost tackling with AI. Dario gets it. Had cancer himself and his father passed away from it.
> For once, this isn’t hyperbole.
Am I missing something?
From other sources:
> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.
>Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades
Not true. The folfirinox chemo regimen was invented a couple of years ago, and it significantly increased the life expectancy and quality of life for terminal pancreatic cancer patients.[0]
[0]https://www.nejm.org/doi/10.1056/NEJMoa1011923